Real-time Estimate Cboe BZX Other stock markets | 5-day change | 1st Jan Change | ||
194.4 USD | -0.31% | | -0.89% | -14.45% |
06-03 | Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio | CI |
05-30 | JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261 | MT |
October 01, 2021 at 03:12 pm
Share
Labcorp announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider. Individuals infected with COVID-19 and flu may experience similar symptoms such as fever, runny and/or stuffy nose and cough. The kit helps people test for both flu and COVID-19 in the safety of their home and avoid the risk of spreading the virus to others. The kit uses a short nasal swab that is inserted into the lower nostril, making it more comfortable and easier for individuals and parents to collect samples at home. Starting in early October, adults 18 and over, as well as parents and guardians of children 2-17 years of age, can request the combined collection kit online through Pixel by Labcorp. In addition, physicians can order the collection kit for children as young as 2 years old directly from their electronic medical record system. The home collection kit is shipped via FedEx Priority Overnight and will include a prepaid return envelope. Test results are available on average between 1-2 days after Labcorp receives the completed collection kit. In most cases, results are available in one day after the kit is received. Results can be accessed conveniently through an individual’s Pixel by Labcorp account, and results from physician ordered tests will be available online through the patient portal and the Labcorp Patient™ app.
Share
© S&P Capital IQ - 2021
Latest news about Labcorp Holdings Inc.
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio | CI | |
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261 | MT | |
Some of the biggest splits in Corporate America | RE | |
Declaration of Voting Results by Laboratory Corporation of America Holdings | CI | |
Declaration of Voting Results by Laboratory Corporation of America Holdings | CI | |
Declaration of Voting Results by Laboratory Corporation of America Holding | CI | |
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing | MT | |
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating | MT | |
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy | CI | |
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal | CI | |
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. | CI | |
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 | MT | |
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy | MT | |
US FDA publishes final rule for laboratory developed tests | RE | |
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B | CI | |
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 | MT | |
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 | MT | |
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating | MT | |
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225 | MT | |
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating | MT | |
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated | MT | |
Transcript : Laboratory Corporation of America Holdings, Q1 2024 Earnings Call, Apr 25, 2024 | ||
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 Revenue $3.18B, vs. Street Est of $3.12B | MT | |
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 EPS $3.68, vs. Street Est of $3.48 | MT | |
Laboratory Corporation of America Holdings Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chart Labcorp Holdings Inc.
More charts
Company Profile
Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Sector
Related indices
More about the company
Income Statement Evolution
More financial data
Ratings for Labcorp Holdings Inc.
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
195USD
Average target price
238.5USD
Spread / Average Target
+22.28%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
1st Jan change | Capi. | |
---|---|---|
LABCORP HOLDINGS INC. | -14.45% | 16.44B |
HCA HEALTHCARE, INC. | +22.71% | 87.14B |
CVS HEALTH CORPORATION | -23.79% | 75.59B |
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY | +1.76% | 26.78B |
+3.99% | 17.89B | |
QUEST DIAGNOSTICS INCORPORATED | +2.76% | 15.68B |
NATERA, INC. | +70.02% | 13.3B |
TENET HEALTHCARE CORPORATION | +76.05% | 13.06B |
FRESENIUS MEDICAL CARE AG | +3.11% | 12.54B |
UNIVERSAL HEALTH SERVICES, INC. | +21.27% | 12.49B |
- Stock Market
- Equities
- LH Stock
- News Labcorp Holdings Inc.
- Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined COVID-19 and Flu Detection